Covid and flu can awaken ‘sleeping' cancer cells, scientists find
Researchers found when mice were exposed to Covid or influenza, dormant cancer cells woke up and spread rapidly.
The inflammatory process, which happens when the body's immune system is activated in response to an infection, can awaken disseminated cancer cells (DCCs). These are cells that have broken away from a primary tumour that can spread to distant organs, often lying dormant for extended periods.
Researchers found that a Covid or influenza infection in the mice sparked a massive expansion of metastatic cells in the lungs within days of infection and the appearance of metastatic lesions within two weeks.
Their analysis, published in the journal Nature, revealed the dormant cells were awoken by interleukin-6 (IL-6) - a protein that immune cells release in response to infections or injuries.
The results are 'really quite dramatic', said James DeGregori, a cancer biologist at the University of Colorado School of Medicine in Aurora, and an author of the study.
'Respiratory virus infections didn't just awaken the cells,' he added. These viruses also caused them to proliferate, or multiply 'to enormous numbers', he said.
'Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames'.
However, two population studies also showed the risk of a virus waking up dormant cancer cells is not just a problem in mice.
The study's authors suggested that respiratory infections in cancer patients in remission are linked to cancer metastasis - where cancer cells spread from the original tumour to other parts of the body.
Researchers used data from patients who were diagnosed with cancer and other diseases prior to the pandemic from the UK Biobank, which holds data from more than 500,000 people.
Researchers from Utrecht University and Imperial College London investigated whether a Covid infection increased the risk of cancer-related mortality among participants with cancer.
They focused on cancer survivors who had been diagnosed at least five years before the pandemic, ensuring they were likely in remission. Among them, 487 individuals tested positive for Covid and these were compared to 4,350 matched controls who tested negative.
After excluding those cancer patients who died from Covid, the researchers found that cancer patients who tested positive for Covid faced an almost doubling of risk of dying from cancer compared to those patients with cancer who had tested negative.
The second population study used data from the US Flatiron Health database and focussed on data from female breast cancer patients seen at 280 US cancer clinics.
They compared the incidence of metastases to the lung among those who did not have Covid (36,216) and patients that tested positive (532).
Participants were followed up just over four years later and researchers found those who came down with Covid were almost 50 per cent more likely to experience metastatic progression to the lungs compared with patients with breast cancer without a diagnosis of Covid.
'Our findings suggest that cancer survivors may be at increased risk of metastatic relapse after common respiratory viral infections,' said Dr Roel Vermeulen of Utrecht University. 'It is important to note that our study focused on the period before Covid-19 vaccines were available.'
'Our findings indicate that individuals with a history of cancer may benefit from taking precautions against respiratory viruses, such as vaccination when available, and discussing any concerns with their healthcare providers,' said Dr Julio Aguirre-Ghiso of MECCC's Cancer Dormancy Institute, a co-leader of the study.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
15 minutes ago
- The Independent
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
The Independent
an hour ago
- The Independent
Doctors decry RFK Jr decision to slash mRNA vaccine grants: ‘Our nation will pay in lives'
Doctors are sounding the alarm about potentially deadly consequences of the Trump administration's decision to slash $500 million in funding for mRNA vaccine development, saying the 'deeply troubling' move could leave Americans defenseless in the face of a biological attack, or another pandemic. Leading physicians and vaccine specialists were among the medical and scientific experts who told The Independent that years of progress had been lost, including the lessons learned during Covid. 'This is a deeply troubling development that will, in the short term, leave the U.S. poorly prepared for a pandemic or biological attack, and, in the long term, stifle medical innovation upon which so many Americans depend for life saving cures,' Dr. Jennifer Nuzzo, director of the Pandemic Center at the Brown University School of Public Health, said in an email. Health and Human Services Sec. Robert F Kennedy Jr announced Tuesday the termination of 22 projects, including contracts with Emory University and Covid shot-makers Moderna, Pfizer, and AstraZeneca. 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,' Kennedy said. While Kennedy, who has questioned Covid vaccine safety and previously falsely claimed the measles vaccine contains fetal debris, cited a review of 'the science' in terminating the project. But Dr Nuzzo said the 'attack on mRNA vaccine technology rests on phony and false claims, proven so by real facts and evidence'. She continued: 'It is, however, aligned with his long-held and deadly determination to sow doubts about all vaccines and to restrict the ability of the American people to access vaccines. Our nation will pay dearly for this decision in dollars and lives.' The mRNA vaccines work differently from traditional vaccines, which inject a weakened virus into the body to trigger an immune response. Instead, mRNA vaccines teach the cells to make small and harmless pieces of virus that trigger the same response. The anti-vaxxer movement and Kennedy have inaccurately claimed that mRNA Covid vaccines are deadly and that vaccines 'poisoned' American children but they are safe according to decades of public research and countless government assessments. The only mRNA vaccines currently available are Covid vaccines. They were able to be brought to market so quickly because scientists didn't need the virus to make them, and the vaccine material can be created in a lab. Research also has been underway to produce mRNA vaccines against cancer and other infectious diseases, work that has been going on for decades. 'While most would associate mRNA vaccine technology with Covid, it was in development for over half a century and the U.S. government's partnership in that development goes back decades,' Richard Hughes IV, a former vice president of public policy at mRNA vaccine manufacturer Moderna who teaches vaccine law at George Washington University Law School, told The Independent. 'These kinds of partnerships are what drive innovation and save us from public health emergencies. When we lose this kind of progress, we create future public health risks.' Scientists know it's only a matter of time before the next pandemic, when vaccines may once again be needed en masse. Dr. Jake Scott, an infectious diseases physician and Clinical Associate Professor at Stanford University School of Medicine, said that no other vaccine technology could provide the world with a vaccine as quickly as is need during a pandemic. He noted that Kennedy's decision was rewriting the history of the pandemic and the lifesaving track record of mRNA vaccines. 'Vaccines aren't some niche drug. We're not talking about some rare skin cancer drug. We're talking about medicines that apply to literally every human being on the planet and we should have learned from the Covid pandemic that everyone is potentially susceptible to pandemic,' Dr Scott said. In what experts have labeled an assault on science, the Trump administration has eliminated grants and dramatically reduced the workforce of federal health and science agencies. Theses actions, and Kennedy's mRNA cuts, are likely in response to government vaccine mandates and restrictions, Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, told The Independent. 'It's a tremendous step backward, the is politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,' he said.
Reuters
an hour ago
- Reuters
US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies
Aug 6 (Reuters) - Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of conspiring to restrict drug discounts offered to community pharmacies that contract with providers serving low-income patients. A three-judge panel of the 2nd U.S. Circuit Court of Appeals in New York ruled, opens new tab that federally funded Mosaic Health and Central Virginia Health Services can move ahead for now with their proposed class action. The appeals court in its unanimous order reversed a decision by a federal judge dismissing the lawsuit. The clinics contend the drugmakers schemed in 2020 to limit discounts on diabetes drugs that were available to safety-net providers purchasing drugs from some pharmacies through a federal program known as "340B." As direct competitors, the four defendants control the diabetes drug marketplace, which would make imposing restrictions "easy to coordinate and maintain,' Circuit Judge Myrna Pérez wrote in the ruling, joined by Circuit Judges Alison Nathan and Maria Araújo Kahn. A Sanofi spokesperson in a statement said the company was reviewing the opinion and considering its next steps. Eli Lilly, Novo Nordisk and AstraZeneca did not immediately respond to requests for comment. The companies have denied any wrongdoing. Brian Feldman, a lead attorney for the health clinics, in a statement called the 2nd Circuit's order a 'watershed moment' and said 'we look forward to seeking justice for safety-net providers.' Mosaic Health operates 22 clinics in New York, and Central Virginia Health Services runs 18 clinics in Virginia. The two clinics sued in 2021 seeking damages for alleged revenue lost from the discount program's savings. The plaintiffs told the appeals court that Sanofi and the other manufacturers made billions of dollars in additional profits 'at the expense of safety-net providers and, ultimately, the patients they serve.' In a court filing, the drugmakers called the plaintiffs' claims 'far-fetched' and said the clinics were trying to punish the companies for implementing policies designed to address what they said were 'well-documented' abuses of the 340B program. Drugmakers must participate in the program to receive funds from government health insurance programs like Medicare and Medicaid. The case is Mosaic Health Inc v. Sanofi-Aventis U.S. LLC et al, 2nd U.S. Circuit Court of Appeals, No. 24-598. For plaintiffs: Brian Feldman of Aurelian Law For defendants: Allon Kedem of Arnold & Porter Kaye Scholer Read more: Wegovy maker Novo hit with investor class action over revenue forecast cut AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action Mylan to pay $73.5 mln to settle drug wholesalers' EpiPen antitrust claims US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit
